June 16, 2023
January 25, 2025
This week’s newsletter included:
-
Denali, Alucent Present to Utah Life Sciences Innovation Caucus
-
Myriad Genetics Announces Research Collaboration to Use Minimal Residual Disease Testing Platform
-
Kuda Therapeutics Success Story Highlighted by Utah Innovation Center
-
Utah Business Announces 2023 CXOs of the Year
-
CancerVax Reports Positive Progress on Kids Cancer Immunotherapy Treatment
-
Purgo Scientific Named as One of 61 Startups in MedTech Accelerator 2023 Cohort
-
Recursion’s Phase 2 Trial for Treatment of Cerebral Cavernous Malformation Has Fully Enrolled
-
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (Intranasal Carbetocin) for Prader-Willi Syndrome
-
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
-
CSBI Releases 2023 Life Sciences Workforce Trends Report
-
New Report Explores Best Practices in State Bioscience Economic Development
-
Ampleo Offers New Services – Fractional CMO
Recent News
- BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
- Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform
- Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
- Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
- GE HealthCare’s Economic Impact Across Utah
- RefloDx Wins Trans Atlantic Angel Grand Prize
